Takeda is committed to bringing better health and a brighter future to people worldwide through leading innovation in medicine. As a patient-driven, science-first R&D organization, Takeda combines cutting-edge technologies with a focus on core therapeutic areas: Oncology, Rare Diseases, Neuroscience, Gastroenterology, Plasma-Derived Therapies and Vaccines.

As a trusted global leader and industry partner who is reimagining plasma and exploring its untapped potential, Takeda's Plasma-Derived Therapies Business Unit is dedicated to transforming the lives of patients worldwide who rely on these lifesaving and life-sustaining therapies.

With an 80-year legacy of developing treatments for rare and complex chronic diseases, we thrive on innovation, offering a broad, differentiated portfolio of more than 20 plasma medicines with integrated care solutions to patients in more than 80 countries.

Powered by ~17,000 Takeda employees, our > 200 high-quality BioLife donation centers, a dedicated R&D team, and eight world-class plasma manufacturing facilities, we are unleashing data, digital and technology to transform our end-to-end operations and set new industry standards.

This enables us to innovatively and sustainably meet the growing and changing needs of patients, our people, and our planet, today and in the future.

This is an initiative organised and funded by Takeda.

Primary Immunodeficiency(PI)

A group of ~485 genetic conditions that affect the immune system(1,2) >50% of patients are unable to produce functioning antibodies(2-4)

Rare: 0.2-87/100,000 people(2)

Symptoms show as severe, persistent or unusual, recurrent infections; increased susceptibility to non-infectious complications of the lung, gut, or autoimmune dysregulation

Diagnosis often delayed for decades

Unmet needs:

• Lack of disease awareness among HCPs
• Complex, multi-stage diagnostic protocol
• Personalized care (Including diagnosis and tailored treatment)

*For more information and source citations, please see official challenge brouchure linked at the top of this page.

1. Tangye SG et al. J Clin Immunol 2022; doi.org/10.1007/s10875-022-01289-3; 2. Rezaei N et al. Introduction on Primary Immunodeficiency Diseases. 2017; 3. Kobrynski L et al. J Clin Immunol 2014;34:954–961; 4. Modell V et al. Immunol Res 2016;64:736–753.

As a guide: 2 main biomarkers recommended to provide provide direction (of a patient suspected of PI)

• Total IgG (including ig isotypes and IgG subclasses)
• CRP (c-reactive protein)




These blood tests are available at any major lab corporation, but are generally only issued after an HCP professional (i.e. immunologist) has ordered the panel.

There is an opportunity to test for PI sooner at any HCP office if the test is non-invasive. This could greatly reduce the time to diagnosis for those suffering with PI.

Takeda PDT is looking for innovative ideas and technologies for non-invasive testing of:
• Total IgG (including Ig isotypes and IgG subclasses)
• CRP (c-reactive protein)

These non-invasive methods can be early-stage tests still in R&D or completely built and shelf ready machines. Technologies should perform at least Total IgG and additionally CRP as an upside. Technologies that can test both in a non-invasive method are the most desirable.

What can Takeda offer you?

• A dedicated point of contact to start your partnership journey with Takeda PDT
• We will tailor our partnership with the needs of the winner solution and based on how well the winning solution meets the challenge objectives. Partnerships can range from Proof-of-Concept funding a Co-Creation Project to Investment and Business Partnership.
• Access to Takeda's Global Resources and Expertise